Back

Empagliflozin ameliorates the cardiac energy-deficient state, improves cardiac function and reduces myocardial cellular volume in patients with type 2 diabetes

7 May 2021 (17:45 - 18:00)
Organised by:
Congress Presentation Part of: Recent trials and breaking studies Epidemiology, Prognosis, Outcome EACVI Premium Access EuroCMR 2021

About the speaker

Photo
Doctor Sharmaine Thiru

Leeds General Infirmary, Leeds (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Cost-Minimization analysis for cardiac revascularization in 12 healthcare systems based on the EuroCMR/SPINS registries
Doctor K. Moschetti (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Large-scale, multi-vendor, multi-protocol, quality-controlled analysis of clinical cine CMR using artificial intelligence
Doctor J. Mariscal Harana (London, GB)
Abstract Slides Video
Presentation thumbnail
Long-term Prognostic Value of Cardiovascular Magnetic Resonance Imaging in Patients with Suspected Cardiac Tumor: A Multicenter Study with 4,285 Patient-years of Follow-up
Professor C. Shenoy (Minneapolis, US)
Slides Video

Access the full session

Session thumbnail
Recent trials and breaking studies
Video

The Event

Event poster

EuroCMR 2021

7 May 2021 17:45 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources